TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01388621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (PLD)
Description: pegylated liposomal doxorubicin (PLD) 30 mg/m² d1 q4w until progressive disease or for a max. of 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated liposomal doxorubicin (PLD)
Description: pegylated liposomal doxorubicin (PLD) 30 mg/m² d1 q4w until progressive disease or for a max. of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1000 mg/m² d1 + 8 q3w until progressive disease or for a max. of 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: gemcitabine 1000 mg/m² d1 + 8 q3w until progressive disease or for a max. of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 9 mg/kg/BW d1 q3w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
Study: NCT02612116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pulverized ticagrelor sublingually
Description: Pulverized ticagrelor (180 mg) administered sublingually

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pulverized ticagrelor orally
Description: Pulverized ticagrelor (180 mg) administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Integral ticagrelor
Description: Integral ticagrelor (180 mg) administered orally
Study: NCT03003832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in electronic health record default for new opioid analgesic prescriptions
Study: NCT01493947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 1% cream
Description: Ivermectin 1% cream applied once daily on the face during 16-week plus 36-week extension period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 0.75% cream
Description: Metronidazole 0.75% cream applied twice daily on the face during 16-week plus 36-week extension period.
Study: NCT01378533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF
Description: epirubicin 80mg/m2 iv d1 or divide in two days cyclophosphamide 600mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d\*4cycles paclitaxel 175mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d\*4cycles paclitaxel 150mg/m2 iv d1 carboplatin AUC=3 iv d2 G-CSF 3ug/kg ih d5-9 q14d\*8cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF
Description: epirubicin 80mg/m2 iv d1 or divide in two days cyclophosphamide 600mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d\*4cycles paclitaxel 175mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d\*4cycles paclitaxel 150mg/m2 iv d1 carboplatin AUC=3 iv d2 G-CSF 3ug/kg ih d5-9 q14d\*8cycles
Study: NCT02530632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: General anesthesia maintained with intravenous propofol infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: General anesthesia maintained with inhalational sevoflurane

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia induction
Description: Induce routine of general anesthesia, including propofol 1-3mg/kg, fentanyl 1-3mcg/kg, cisatracurium 0.2-0.3mg/kg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia induction
Description: Induce routine of general anesthesia, including propofol 1-3mg/kg, fentanyl 1-3mcg/kg, cisatracurium 0.2-0.3mg/kg.
Study: NCT04034433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Handgrip exercise program
Description: Handgrip exercise with a rubber ball 4 weeks before the surgery until 4 weeks after the surgery 20 contractions per minute for a total of 20 minutes each day.
Study: NCT01420796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swallowing exercise
Description: Patients will perform oral motor exercises for swallowing muscles for five weeks, four days a week.~This exercises aim to increase strength and range of motion of mouth, larynx and pharynx structures. All patients will make sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercises
Description: Patients will perform expiratory muscle training. Initial load will be 30% of maximal expiratory pressure which will increase until 75%. This load will be keep until end of training. Patients will made the exercises for 30 minutes with three minutes of training and two of rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swallowing and breathing exercises
Description: For five weeks, patients will perform swallowing and breathing exercises that follow: expiratory muscle training and sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.
Study: NCT02785406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suvorexant
Description: Subjects will receive suvorexant capsules (10 mg week 1, 20 mg week 2), once daily at 10 PM.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for suvorexant)
Description: Subjects will receive placebo capsules once daily at 10 PM.
Study: NCT02520635

Intervention type: DRUG
Intervention: supra-early TEMODAL® chemotherapy

Intervention type: DRUG
Intervention: standard TEMODAL® chemotherapy

Intervention type: RADIATION
Intervention: Radiotherapy 60Gy

Intervention type: RADIATION
Intervention: Radiotherapy 60Gy
Study: NCT04345731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Over the counter drug labels
Description: A control condition based on the current standard OTC label and 3 experimental labels will be compared to identify OTC labels that more effectively communicate critical information for the reduction of adverse drug events to the consumer
Study: NCT03579745

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lingual orthodontics
Description: A coil spring will be attached from the lever arm to the first molar tube

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lingual orthodontics
Description: A coil spring will be attached from the lever arm to the first molar tube
Study: NCT01032967

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: The patients will receive standard open esophagectomy with two-field lymphadenectomy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Definitive chemoradiation
Description: 3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in a three-dimensional conformal mode (total of 50-60 Gy given in 25-30 fractions) will be given over a period 5-6 weeks.
Study: NCT01155947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
Study: NCT04642638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-4800
Description: INO-4800 was administered ID on Day 0 and Day 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-4800
Description: INO-4800 was administered ID on Day 0 and Day 28.
Study: NCT01731444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Study: NCT04345731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Over the counter drug labels
Description: A control condition based on the current standard OTC label and 3 experimental labels will be compared to identify OTC labels that more effectively communicate critical information for the reduction of adverse drug events to the consumer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Over the counter drug labels
Description: A control condition based on the current standard OTC label and 3 experimental labels will be compared to identify OTC labels that more effectively communicate critical information for the reduction of adverse drug events to the consumer
Study: NCT00802269

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retinal laser photocoagulation
Description: Retinal laser photocoagulation using a 532 nm laser

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retinal laser photocoagulation
Description: Retinal laser photocoagulation using a 532 nm laser
Study: NCT01485224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Eligible patients will receive thalidomide at a starting dose of 50 mg/day by mouth at bedtime for 4 weeks. In the event of unsatisfactory/no response, thalidomide dosage will be progressively increased by 50 mg/day every 4 weeks until complete or partial response, to a maximum dose of 200 mg/day.~Treatment will be continued until one of the following criteria is met:~* 8 additional weeks of treatment after the achievement of complete response~* 16 additional weeks of treatment after the achievement of partial response~* 24 weeks of treatment completed without response~* unacceptable toxicity. Then, patients will be followed off of thalidomide for 24 weeks.
Study: NCT02205866

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial Receptivity Array analysis of endometrial biopsy
Description: A biopsy of endometrium is peformed and Endometrial Receptivity Array analysis is carried out, as well as analysis of fat distribution and risk factors of Metabolic Syndrome.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endometrial Receptivity Array analysis of endometrial biopsy
Description: A biopsy of endometrium is peformed and Endometrial Receptivity Array analysis is carried out, as well as analysis of fat distribution and risk factors of Metabolic Syndrome.
Study: NCT01557452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givinostat
Description: ready-to-use oral suspension, administered in fed condition and on a outpatient basis, especially intended for paediatric patients
Study: NCT01328054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: lapatinib commercial tablet, 2000mg, will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo matching lapatinib
Description: placebo matching lapatinib will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period
Study: NCT05424107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KIDMED
Description: Pre-and post-intervention evaluation of the adherence to the Mediterranean diet and its effect on prediabetic state, as well as, other anthropometric values.
Study: NCT02277795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuCirc
Description: Circumcision with the use of the AccuCirc device.
Study: NCT00227656

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2a
Description: Once a week subcutaneous injection for 21 days, beginning at 180 mcg per week. Repeated for additional 21 days to begin at the same time as repeat 21 day Capecitabine cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m\^2 twice daily during first 14 days of each 3-week cycle (2 weeks on, 1 week rest).
Study: NCT02128867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assisted Autogenic Drainage (AAD)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bouncing and AAD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bouncing
Study: NCT03078803

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant (FMT)
Description: FMT delivered by colonoscopy and oral capsules

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Transfer of water only
Study: NCT03565666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
Description: iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iLet Bionic Pancreas insulin-only configuration with Fiasp
Description: iLet Bionic Pancreas insulin-only configuration with Fiasp (faster insulin aspart)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care
Study: NCT01292460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol/ FDC/ Placebo/ Tafluprost
Description: Prior timolol users: Timolol (administered at 08:00 and 20:00) or FDC of tafluprost and timolol (at 08:00) and Placebo eye drops (at 20:00).~Prior prostaglandin users: Tafluprost (administered at 08:00) or FDC of tafluprost and timolol (administered at 08:00).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol/ FDC/ Placebo/ Tafluprost
Description: Prior timolol users: Timolol (administered at 08:00 and 20:00) or FDC of tafluprost and timolol (at 08:00) and Placebo eye drops (at 20:00).~Prior prostaglandin users: Tafluprost (administered at 08:00) or FDC of tafluprost and timolol (administered at 08:00).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol/ FDC/ Placebo/ Tafluprost
Description: Prior timolol users: Timolol (administered at 08:00 and 20:00) or FDC of tafluprost and timolol (at 08:00) and Placebo eye drops (at 20:00).~Prior prostaglandin users: Tafluprost (administered at 08:00) or FDC of tafluprost and timolol (administered at 08:00).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol/ FDC/ Placebo/ Tafluprost
Description: Prior timolol users: Timolol (administered at 08:00 and 20:00) or FDC of tafluprost and timolol (at 08:00) and Placebo eye drops (at 20:00).~Prior prostaglandin users: Tafluprost (administered at 08:00) or FDC of tafluprost and timolol (administered at 08:00).
Study: NCT02182960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen syrup

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brufen syrup
Study: NCT03070431

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-precision RT 5x5 Gy in 1 week
Description: Patients included in this study will receive a high-precision radiotherapy with 5x5 Gy in 1 week
Study: NCT04681274

Intervention type: DEVICE
Intervention: Image features extraction and clustering
Description: The image processing operations required for local content-based image feature extraction consist of two main tasks: 1) tiling the images in smaller VOIs, typically a small cube, whose size depends on the modality, on the image resolution and on the purpose of the content-based query, and 2) performing feature extraction operations on the VOIs.~The Feature Extraction Engine performs totally unsupervised, automatic and asynchronous extractions of features from the images, organizes and indexes them in a no-SQL database based on unique similarity metric. The results of this phase are a series of clusters of phenotype signatures.

Intervention type: DEVICE
Intervention: Phenotype signature database building
Description: Since the clusters are self-organizing their pathophysiological meaning is not readily apparent and requires further analysis. The characterization of each cluster is performed by analyzing representative samples and their respective correlation with histopathology results. After a series of iterations, the clusters are organized to correlate with distinct tissue subtypes identified by their signature similarity. The final number of clusters is not known a priori and depends on the heterogeneity of the underlying imaging phenotypes.
Study: NCT01463683

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2XP HEPTAVAX™-II SC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 1XP HEPTAVAX™-II SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2XP HEPTAVAX™-II IM
Study: NCT01016496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: action observation therapy
Description: 15 consecutive sessions of 18 minutes, plus repetition

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: repetition of gestures
Description: 15 consecutive session of visual games, plus repetition of gestures
Study: NCT01956227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Description: exercise to look at balance and lower limb strength record in diary

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: sessions to discuss self-management ideas to modify risk of falling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise plus Education
Description: combination of exercise sessions with education sessions to modify fall risk
Study: NCT03536819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Votiva
Description: The applicator uses radio-frequency energy to treat the vaginal canal
Study: NCT03586830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111 Dose Level 1
Description: Participants will receive JNJ-64565111 Dose Level 1 SC once-weekly until Week 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111 Dose Level 2
Description: Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111 Dose Level 3
Description: Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 12.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo to JNJ-64565111 SC once-weekly until Week 12.
Study: NCT03158428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD170202AA
Description: A moist snuff product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD170202AA
Description: A moist snuff product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD170202AB
Description: A moist snuff product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD170202AB
Description: A moist snuff product
Study: NCT01000857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine CR and Paroxetine IR
Description: Randomized, 2-period crossover repeat dosing of Paroxetine CR at 25 mg/day for 14 days and Paroxetine IR at 20 mg/day for 14 days in Japanese healthy male volunteers
Study: NCT00527397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-464,005
Description: Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-464,005
Description: Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-464,005
Description: Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose:adjusted based on the results of self-monitoring of blood glucose before each meal.
Study: NCT04211272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan will be administrated as film-coated tablet in Part A and Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan will be administrated as film-coated tablet in Part A and Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil will be administrated as film-coated tablet in Part A.
Study: NCT03055780

Intervention type: DEVICE
Intervention: CT-FFR. CTA. FFR
Description: Study is to compare results of CT FFR against CTA and interventional FFR
Study: NCT04298970

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Freeze-dried Brassica oleracea var. acephala

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product
Study: NCT04211272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat
Description: Riociguat will be administrated as film-coated tablet in Part A.
Study: NCT04178460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib combined with MGD013
Description: The dose escalation part will enroll about 9 - 24 Gastric cancer (including gastroesophageal junction cancer) subjects, with fixed dose niraparib (200mg or 300mg) combined with MGD013 (120mg, 300mg or 600mg ) in different dose level.~For the dose expansion part, patients with advanced or metastatic Gastric cancer (including gastroesophageal junction cancer), Triple negative breast cancer, Biliary tract carcinoma, Endometrial carcinoma will be enrolled, about 35 subjects for each expansion cohort during dose expansion phase with fixed dose niraparib (200mg or 300mg) combined with fixe dose MGD013 (to be confirmed after dose escalation).
Study: NCT04211272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin will be administrated as film-coated tablet in Part B.
Study: NCT01387308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Oral tablets, 50 mg x 2, single dose

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Fostamatinib
Description: Oral tablets, 50 mg x 3, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Oral tablets, 100 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Oral tablets, 150 mg, single dose
Study: NCT03137641

Intervention type: OTHER
Intervention: Nurses urine samples
Description: Collected urine samples from nurses in contact with antineoplastic drugs.